Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other financing activities (2016 - 2025)

Amphastar Pharmaceuticals has reported Other financing activities over the past 9 years, most recently at $8000.0 for Q4 2025.

  • Quarterly results put Other financing activities at $8000.0 for Q4 2025, up 136.36% from a year ago — trailing twelve months through Dec 2025 was $687000.0 (down 15.81% YoY), and the annual figure for FY2025 was $687000.0, down 15.81%.
  • Other financing activities for Q4 2025 was $8000.0 at Amphastar Pharmaceuticals, up from $4000.0 in the prior quarter.
  • Over the last five years, Other financing activities for AMPH hit a ceiling of $10.4 million in Q3 2023 and a floor of -$22000.0 in Q4 2024.
  • Median Other financing activities over the past 5 years was $252000.0 (2024), compared with a mean of $876466.7.
  • Biggest five-year swings in Other financing activities: tumbled 104.49% in 2024 and later surged 25400.0% in 2025.
  • Amphastar Pharmaceuticals' Other financing activities stood at $308000.0 in 2021, then tumbled by 99.03% to $3000.0 in 2022, then skyrocketed by 16233.33% to $490000.0 in 2023, then tumbled by 104.49% to -$22000.0 in 2024, then skyrocketed by 136.36% to $8000.0 in 2025.
  • The last three reported values for Other financing activities were $8000.0 (Q4 2025), $4000.0 (Q3 2025), and $253000.0 (Q2 2025) per Business Quant data.